KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Total Liabilities (2016 - 2026)

Amgen has reported Total Liabilities over the past 18 years, most recently at $83.3 billion for Q1 2026.

  • For Q1 2026, Total Liabilities changed 0.19% year-over-year to $83.3 billion; the TTM value through Mar 2026 reached $83.3 billion, changed 0.19%, while the annual FY2025 figure was $81.9 billion, 4.69% down from the prior year.
  • Total Liabilities for Q1 2026 was $83.3 billion at Amgen, up from $81.9 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $90.9 billion in Q4 2023 and troughed at $56.9 billion in Q2 2022.
  • A 5-year average of $78.2 billion and a median of $83.2 billion in 2025 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 47.94% in 2023 and later fell 5.46% in 2024.
  • Year by year, Total Liabilities stood at $61.5 billion in 2022, then soared by 47.94% to $90.9 billion in 2023, then dropped by 5.46% to $86.0 billion in 2024, then decreased by 4.69% to $81.9 billion in 2025, then grew by 1.69% to $83.3 billion in 2026.
  • Business Quant data shows Total Liabilities for AMGN at $83.3 billion in Q1 2026, $81.9 billion in Q4 2025, and $80.5 billion in Q3 2025.